Oxaliplatin, irinotecan, bevacizumab followed by docetaxel, bevacizumab in inoperable gastric cancer: First efficacy results of a multicenter phase II trial (AGMT Gastric-3) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie.
Ewald Woell
Honoraria - Pfizer; Roche; Sanofi
Other Remuneration - Pfizer; Roche; Sanofi
Josef Thaler
No relevant relationships to disclose
Felix Keil
No relevant relationships to disclose
Wolfgang Eisterer
No relevant relationships to disclose
Michael A. Fridrik
Consultant or Advisory Role - Pfizer; Roche; Sanofi
Honoraria - Pfizer; Roche; Sanofi
Research Funding - Pfizer; Roche; Sanofi
Other Remuneration - Pfizer; Roche; Sanofi
Birgit Gruenberger
No relevant relationships to disclose
Michael Hejna
No relevant relationships to disclose
Franz Romeder
No relevant relationships to disclose
Richard Greil
No relevant relationships to disclose